<DOC>
	<DOCNO>NCT00106028</DOCNO>
	<brief_summary>Children Osteogenesis Imperfecta ( OI ) bone pain , low bone mass fracture . There approved drug treatment OI child , even though intravenous ( IV ) bisphosphonates used off-label country . In single dose , pharmacokinetic study , data show risedronate well tolerate 28 child OI . This three year study test safety efficacy risedronate treatment child OI . For first year , patient randomize risedronate placebo group 2:1 ratio . For second third year study , patient receive risedronate .</brief_summary>
	<brief_title>Safety Efficacy Risedronate Treatment Osteogenesis Imperfecta Children</brief_title>
	<detailed_description />
	<mesh_term>Osteogenesis Imperfecta</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>OI diagnosis increase risk fracture : either history least 1 radiographically confirm , nontraumatic low impact fracture plus low bone mineral density ( BMD ) low BMD without history fracture . Any bisphosphonate use within one year enrollment</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Primary disease : Osteogenesis Imperfecta</keyword>
</DOC>